Related Experiment Video
Updated: Mar 18, 2026
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
8.4K
New Antituberculosis Drugs: From Clinical Trial to Programmatic Use
Gina Gualano1, Susanna Capone2, Alberto Matteelli2
1Respiratory Infectious Diseases Unit, National Institute for Infectious Diseases L. Spallanzani , Rome.
Infectious Disease Reports
|July 13, 2016
Summary
New drugs like bedaquiline and delamanid offer hope for treating multidrug-resistant tuberculosis (MDR-TB). Responsible adoption and ongoing clinical trials for shorter, all-oral regimens are crucial for improving MDR-TB outcomes.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Multidrug-resistant tuberculosis (MDR-TB) treatment is challenging due to less effective and more toxic second-line drugs.
- Current MDR-TB treatment outcomes are generally poor, necessitating novel therapeutic agents.
- The development of new anti-TB drugs is critical for improving patient outcomes.
Purpose of the Study:
- To review the current landscape of multidrug-resistant tuberculosis (MDR-TB) treatment.
- To highlight the introduction and efficacy of new anti-TB drugs, bedaquiline and delamanid.
- To discuss the role of repurposed drugs and ongoing clinical trials for novel MDR-TB regimens.
Main Methods:
- Review of recent clinical trial data for new anti-TB drugs.
- Analysis of treatment guidelines and recommendations for MDR-TB.
- Evaluation of repurposed drugs and emerging therapeutic strategies.
Main Results:
- Bedaquiline and delamanid have demonstrated improved sputum culture conversion rates and treatment outcomes in MDR-TB patients.
- Repurposed drugs like linezolid and carbapenems show promise for treating resistant TB strains.
- Ongoing phase III trials are investigating shorter, all-oral regimens for MDR-TB treatment.
Conclusions:
- The introduction of bedaquiline and delamanid represents a significant advancement in MDR-TB treatment.
- Responsible implementation of new drugs and further research into novel regimens are essential.
- Specialized centers may be beneficial for managing MDR-TB cases and preventing further resistance.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
737
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
737
01:26Pulmonary Tuberculosis IV
617
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
617
01:28Pulmonary Tuberculosis II
1.9K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.9K
01:29Pulmonary Tuberculosis I
1.2K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.2K
01:31Pulmonary Tuberculosis III
1.3K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.3K
01:29Therapeutic Drug Monitoring: Affecting Factors
316
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
316